Compare Dyne Therapeutics Inc. Common Stock (DYN) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs BlackRock TCP Capital Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while BlackRock TCP Capital Corp trades at $4.07 (market cap $335.61M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 8.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| DYN | TCPC | |
|---|---|---|
Market Cap | $2.86B | $335.61M |
Volume | 3,341,579 | 435,738 |
Sector | Health | Financials |
52-Week High | $26.78 | $6.20 |
52-Week Low | $14.60 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $2.18B | $1.09B |
Dividend Yield | — | 19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TCPC trades at $3.98, showing no daily change. The stock exhibits a bullish technical signal, with moving averages supporting an uptrend. Recent Q2 2026 earnings beat expectations at $0.22 per share, and a $523 million portfolio sale has reduced leverage. However, fundamentals show negative revenue and net income trends, with a net loss of $88.93 million in 2025. The company maintains a dividend, with a $0.17 payment scheduled for September 2026.
The outlook is mixed. Positive technicals and strategic portfolio sales provide support, but persistent losses and a class action lawsuit pose significant risks. Analyst sentiment is cautious, with a majority recommending Hold. Investment potential hinges on the success of the strategic review and future profitability improvements amid ongoing financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
